Detalhe da pesquisa
1.
The PI3K Pathway in Human Disease.
Cell
; 170(4): 605-635, 2017 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802037
2.
Leveraging model-based study designs and serial micro-sampling techniques to understand the oral pharmacokinetics of the potent LTB4 inhibitor, CP-105696, for mouse pharmacology studies.
Xenobiotica
; 47(7): 600-606, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27435693
3.
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Bioorg Med Chem Lett
; 23(9): 2787-92, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23506825
4.
Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.
Bioorg Med Chem Lett
; 22(24): 7605-9, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23116892
5.
Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
Bioorg Med Chem Lett
; 22(15): 5098-103, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22749419
6.
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
Sci Rep
; 12(1): 12501, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35864202
7.
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
Bioorg Med Chem Lett
; 21(4): 1270-4, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21269826
8.
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
J Med Chem
; 64(1): 644-661, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356246
9.
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Bioorg Med Chem Lett
; 20(20): 6096-9, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20817449
10.
The Cbl proteins are binding partners for the Cool/Pix family of p21-activated kinase-binding proteins.
FEBS Lett
; 550(1-3): 119-23, 2003 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-12935897
11.
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
PLoS One
; 8(6): e67258, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23826249
12.
Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
Pigment Cell Melanoma Res
; 25(6): 819-31, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22883054
13.
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.
PLoS One
; 7(6): e39653, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22745804
14.
Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
Mol Cancer Ther
; 11(10): 2274-83, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22752429
15.
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Mol Cancer Ther
; 10(11): 2189-99, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21750219
16.
Src and Wnt converge to seal cell's fate.
Mol Cell
; 10(1): 10-1, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12150902